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Background: Transthyretin (TTR) amyloidosis is a genotype- and phenotype-heterogeneous disease. We describe TTR amyloidosis phenotypes in the 
global Transthyretin Amyloidosis Survey (THAOS)patient registry.
methods: Symptomatic patients were categorized into one of three phenotypes: (a) Cardiac: those with heart failure, dyspnea or cardiac rhythm 
disturbance and minimal or no neurologic or gastrointestinal (GI) symptoms; (b) Neurologic: those with neurologic symptoms, including walking 
disability, or GI symptoms of any severity; (c) Mixed: those not meeting either cardiac or neurologic criteria. Characteristics of each group were 
examined.
results: The cardiac group (n=188) was the oldest at age of disease onset (mean ± standard deviation 61.5 ± 14.3 years; neurologic, n=561, 
44.7 ± 14.3 years; mixed, n=256, 58.4 ± 15.5 years). The most common genotypes within the cardiac phenotype were wild-type (WT; 44.1%), 
V122I (30.5%) and V30M (28.6%). Most neurologic patients had the V30M mutation (82.6%). Common mutations among mixed patients were 
V30M (59.8%), WT (10.5%) and V122I (7.9%). Kaplan-Meier curves show better survival for patients without cardiac involvement (Figure; cardiac vs. 
neurologic P<0.001; mixed vs. neurologic P<0.001).
conclusions: Cardiac involvement with or without neurologic involvement is associated with reduced survival in a large cohort with TTR 
amyloidosis.Data for this abstract are derived from the THAOS registry, which is sponsored by Pfizer Inc.
 
